1Richardson PG, Barlogie B, Berenson J, et al. Extended follow-up of a phase Ⅱ trial in relapsed, refractory multiple myeloma :final time-to-event results from the SUMMIT trial [ J] . Cancer ,2006, 106(6) :1316-1319.
2Chanan-kena A, Miller K C. Velcade, Doxil and Thalidomide (VDT) is an effective salvage regimenn for patients with relapsed and refractory multiple myeloma [ J]. Leuk Lymphoma,2005, 46 (7) : 1103-1104.
3Barlogie B, Zangari M, Bolejack V, et al. Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma [J]. Clin Lymphoma Myeloma, 2006,6 (6) :469-474.
5RICHARDSON P G,BARLOGIE B, BERENSON J, et al. Extended follow-up of a phase Ⅱ trial in relapsed , refractory multiple myeloma [J]. Cancer, 2006,106:1316-1319.
6CHANAN-KENA A, MILLER K C. Veleade, Doxil and Thalidomide(VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma[J]. Leukemia&lymphoma, 2005,46:1103-1104.
7BLADEJ, SAMSON D, REECE D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and haemopoietic stem cell transplantation . Myeloma Subcommitte for the EBMT[J]. Br J haematol, 1998, 102:1115-1123.
8ADAMS J. The proteasome:structure, function , and role in the cell[J]. Cancer Treat Rev, 2003,29:3-9.
9SHAH S,POTTER M,CALLERY M. Ubiquitin proteasome pathway: implication and advances in cancer therapy[J]. Surgical Oncology, 2001,10:43-52.
10KARIN M, CAO Y, GRETEN F, et al. NF-KB in cancer :from innocent bystander to major culprit[J]. Nature Rev Cancer, 2002,2:301-310.
